World Bulletin of Public Health (WBPH)
Available Online at: https://www.scholarexpress.net
Volume-32, March 2024
ISSN: 2749-3644

THE COURSE OF ANEMIA IN DIFFUSE TOXIC GOITER

Kurbanova G.Ch.
Babajanova Sh.A.
Tashkent Medical Academy

Article history:
Received: January 24th 2024
Accepted: March 20th 2024

Abstract:
Anemia is a multifaceted concern in patients with diffuse toxic goiter, commonly known as Graves' disease. This review aims to consolidate existing knowledge regarding the prevalence, etiology, and clinical course of anemia in individuals with diffuse toxic goiter. Through an extensive literature search, we explore the complex interplay between thyroid dysfunction and anemia, encompassing various mechanisms such as increased metabolic demand, malabsorption, autoimmune processes, medication side effects, and associated comorbidities. We discuss the diverse manifestations of anemia in diffuse toxic goiter, including iron deficiency, pernicious anemia, autoimmune hemolytic anemia, and bone marrow suppression. Furthermore, we elucidate the diagnostic challenges and prognostic implications associated with anemia in this context. Importantly, we underscore the necessity of vigilant screening, appropriate diagnostic evaluation, and tailored management strategies to effectively address anemia and optimize clinical outcomes in patients with diffuse toxic goiter. By synthesizing current evidence, this review provides valuable insights into understanding and managing the course of anemia in the context of diffuse toxic goiter.

Keywords: Diffuse toxic goiter, Graves' disease, anemia, thyroid dysfunction, iron deficiency, pernicious anemia, autoimmune hemolytic anemia, bone marrow suppression, diagnosis, management.

The course of anemia in diffuse toxic goiter, also known as Graves' disease, can vary depending on several factors, including the severity of thyroid dysfunction, the presence of comorbidities, and the effectiveness of treatment. Here's a breakdown of key points regarding the course of anemia in diffuse toxic goiter:

PREVALENCE: Anemia is relatively common in individuals with diffuse toxic goiter, with studies reporting varying prevalence rates. It often occurs concurrently with hyperthyroidism but may persist even after thyroid function has been normalized.

TYPES OF ANEMIA:

Iron Deficiency Anemia: This is one of the most common types of anemia associated with diffuse toxic goiter. It may result from increased metabolic demand, gastrointestinal disturbances leading to malabsorption, or menstrual irregularities in women. Iron deficiency anemia is a common type of anemia characterized by a lack of sufficient iron in the body to produce an adequate amount of hemoglobin, which is essential for carrying oxygen in the blood.

Etiology: Inadequate dietary intake of iron-rich foods is a primary cause, particularly in populations with poor nutritional habits. Blood loss, whether from acute bleeding (e.g., gastrointestinal bleeding, menstruation) or chronic low-level loss (e.g., gastrointestinal disorders like ulcers, gastritis, or colorectal cancer), can deplete iron stores. Poor iron absorption due to gastrointestinal disorders (e.g., celiac disease, inflammatory bowel disease) or surgical procedures (e.g., gastric bypass surgery) can lead to iron deficiency. Increased demand for iron during periods of rapid growth (e.g., infancy, adolescence) or pregnancy can outstrip supply, leading to deficiency if dietary intake is insufficient.

Pathophysiology: Iron is a critical component of hemoglobin, the protein in red blood cells responsible for carrying oxygen from the lungs to tissues throughout the body. In iron deficiency anemia, insufficient iron impairs hemoglobin production, resulting in smaller and paler red blood cells (microcytic and hypochromic), reducing the blood's oxygen-carrying capacity.

Clinical Manifestations: Symptoms may include fatigue, weakness, pallor, shortness of breath, dizziness, headache, cold intolerance, brittle nails, and pica (craving for non-food items). Severe or chronic iron deficiency anemia can lead to complications such as tachycardia, angina, heart failure, and impaired cognitive function.

Diagnosis: Diagnosis is based on clinical presentation, blood tests (including complete blood count and iron studies), and evaluation of potential underlying causes.

World Bulletin of Public Health (WBPH)
Available Online at: https://www.scholarexpress.net
Volume-32, March 2024
ISSN: 2749-3644

Laboratory findings typically include low hemoglobin and hematocrit levels, reduced mean corpuscular volume (MCV), decreased serum iron, low ferritin levels (indicating depleted iron stores), and elevated total iron-binding capacity (TIBC).

Treatment: Treatment aims to replenish iron stores and correct the anemia. Oral iron supplementation is usually the first-line therapy for mild to moderate iron deficiency anemia. In cases of severe anemia, intolerance to oral iron, or when rapid correction is needed, intravenous iron therapy may be necessary. Addressing underlying causes (e.g., treating gastrointestinal bleeding, dietary modifications) is crucial to prevent recurrence.

Prognosis: Iron deficiency anemia is generally responsive to treatment, and symptoms improve with correction of the underlying iron deficiency. However, recurrence is common if underlying causes are not adequately addressed or if predisposing factors persist. Early recognition, accurate diagnosis, and appropriate management are essential to effectively treat iron deficiency anemia and prevent associated complications.

Pernicious Anemia:

Pernicious anemia is a type of megaloblastic anemia characterized by a deficiency of vitamin B12 (cobalamin) due to impaired absorption, typically resulting from autoimmune destruction of the gastric parietal cells or other factors affecting the absorption of vitamin B12. Here's an overview of pernicious anemia:

Etiology: Autoimmune gastritis: In pernicious anemia, the body's immune system attacks and destroys the gastric parietal cells, which produce intrinsic factor—a protein necessary for the absorption of vitamin B12 in the ileum.

Other causes: Less commonly, pernicious anemia can result from gastric surgery (e.g., gastrectomy), certain medications, or other conditions affecting the stomach or small intestine.

Pathophysiology: Intrinsic factor deficiency: Autoimmune destruction of gastric parietal cells leads to reduced or absent production of intrinsic factor, impairing the absorption of vitamin B12. Vitamin B12 deficiency: Inadequate absorption of vitamin B12 leads to decreased levels of active B12 in the body, affecting DNA synthesis and resulting in the production of large, immature red blood cells (megaloblasts) in the bone marrow.

Clinical Manifestations: Symptoms may include fatigue, weakness, pallor, shortness of breath, palpitations, glossitis (inflammation of the tongue), gastrointestinal disturbances (e.g., nausea, diarrhea), neurological symptoms (e.g., numbness or tingling in the hands and feet, difficulty walking), and neuropsychiatric symptoms (e.g., memory loss, depression, psychosis). Neurological manifestations, known as subacute combined degeneration of the spinal cord, can occur due to vitamin B12 deficiency affecting the myelin sheath of nerves.

Diagnosis: Diagnosis is based on clinical presentation, laboratory tests, and confirmatory findings. Laboratory findings typically include macrocytic (enlarged) red blood cells, hypersegmented neutrophils, low serum vitamin B12 levels, and elevated levels of homocysteine and methylmalonic acid. Serological testing for antibodies against intrinsic factor or parietal cells may help confirm autoimmune etiology.

Treatment: Lifelong vitamin B12 replacement therapy is the cornerstone of treatment for pernicious anemia. Intramuscular or subcutaneous injections of vitamin B12 bypass the need for intrinsic factor and ensure adequate absorption. High-dose oral vitamin B12 supplements may be effective in some cases, particularly if intrinsic factor-independent absorption pathways are intact. Treatment also involves addressing any underlying autoimmune gastritis and monitoring for potential complications.

Prognosis: With appropriate treatment, symptoms of pernicious anemia typically improve, and hematological parameters normalize. Neurological symptoms may improve with vitamin B12 supplementation but can be irreversible if not promptly treated. Regular monitoring and lifelong vitamin B12 therapy are necessary to prevent recurrence and manage potential complications. Early recognition, diagnosis, and initiation of vitamin B12 replacement therapy are crucial to prevent irreversible neurological damage and improve outcomes in patients with pernicious anemia.

Autoimmune Hemolytic Anemia: Graves' disease is an autoimmune disorder and can be associated with other autoimmune conditions such as autoimmune hemolytic anemia, where the body's immune system attacks its red blood cells. Autoimmune hemolytic anemia (AIHA) is a rare but serious condition characterized by the destruction of red blood cells (RBCs) by the body's immune system. Here's an overview of autoimmune hemolytic anemia:

Etiology: Autoimmune reaction: In AIHA, the immune system produces antibodies that target and destroy the body's own red blood cells. The exact cause of this autoimmune response is often unknown. Underlying conditions: AIHA can occur in association with other autoimmune diseases (such as systemic lupus erythematosus, rheumatoid arthritis), certain infections (e.g., viral infections like Epstein-Barr virus, cytomegalovirus), lymphoproliferative disorders (e.g., lymphoma, chronic lymphocytic leukemia), and drug reactions.

World Bulletin of Public Health (WBPH)
Available Online at: https://www.scholarexpress.net
Volume-32, March 2024
ISSN: 2749-3644

Pathophysiology: Antibody-mediated destruction: Autoantibodies, typically of the IgG or IgM type, bind to antigens on the surface of RBCs, leading to their premature destruction in the spleen or liver by phagocytic cells (macrophages). Complement activation: In some cases, the antibody-coated RBCs may also activate the complement system, further contributing to hemolysis.

Clinical Manifestations: Symptoms of AIHA can vary widely in severity and may include fatigue, weakness, pallor, shortness of breath, jaundice (yellowing of the skin and eyes), dark urine (due to hemoglobinuria), and splenomegaly (enlargement of the spleen). Acute exacerbations of AIHA may present with sudden onset of severe anemia and symptoms of hemolytic crisis, such as rapid heart rate, hypotension, and shock.

Diagnosis: Laboratory tests: Diagnosis is based on clinical suspicion and laboratory findings, including evidence of hemolysis (e.g., elevated serum lactate dehydrogenase, decreased haptoglobin levels), presence of spherocytes on peripheral blood smear, and a positive direct antiglobulin test (Coombs test). Bone marrow examination: Bone marrow aspiration and biopsy may be performed to evaluate for underlying causes or assess for increased erythropoiesis in response to hemolysis.

Treatment: Corticosteroids: First-line treatment for AIHA involves high-dose corticosteroids (e.g., prednisone) to suppress the immune response and reduce hemolysis. Immunosuppressive therapy: For refractory cases or those requiring prolonged treatment, additional immunosuppressive agents (e.g., rituximab, azathioprine, cyclophosphamide) may be used. Supportive care: Treatment also includes supportive measures such as blood transfusions to correct anemia and symptomatic management of complications.

Prognosis: The prognosis of AIHA varies depending on the underlying cause, severity of hemolysis, response to treatment, and presence of comorbidities. While many cases of AIHA respond well to treatment, some individuals may experience relapses or develop complications such as thromboembolism or infections. Management of AIHA requires a multidisciplinary approach involving hematologists, immunologists, and other specialists to tailor treatment to individual patient needs and address underlying conditions contributing to hemolysis. Close monitoring and long-term follow-up are essential to optimize outcomes and prevent recurrence.

Course During Treatment:

Thyroid Function Normalization: Treatment modalities for Graves' disease, such as antithyroid medications, radioactive iodine therapy, or thyroidectomy, aim to normalize thyroid function. As thyroid hormone levels come under control, metabolic demands decrease, which may alleviate anemia in some cases.

Persistent Anemia: However, some patients may continue to experience anemia despite successful treatment of hyperthyroidism. This could be due to factors such as ongoing nutritional deficiencies, residual autoimmune processes, or the presence of other underlying conditions.

Monitoring and Management:

Regular monitoring of hemoglobin levels and other hematological parameters is essential during the course of treatment for diffuse toxic goiter.

Management strategies for anemia may include iron supplementation, vitamin B12 injections or oral supplements, addressing underlying gastrointestinal issues, and managing any associated autoimmune conditions.

Prognosis:

The prognosis for anemia in diffuse toxic goiter largely depends on the underlying cause, response to treatment, and the presence of any complications or comorbidities.

Prompt diagnosis, appropriate management, and close follow-up can help improve outcomes and alleviate symptoms associated with anemia in individuals with diffuse toxic goiter.

Overall, while anemia is a common complication of diffuse toxic goiter, its course and management require individualized approaches tailored to address the underlying causes and associated factors. Regular monitoring and collaboration between endocrinologists and hematologists are often necessary for optimal patient care.

REFERENCES

1) Курбанова, Г. Ч., and Ш. А. Бабаджанова. *Обмен белка при диффузно-токсическом зобе*. Diss. Проблемы биофизики и биохимии, 2021.
2) Бабаджанова, Ш. А., and Г. Ч. Курбанова. *Осмотическая стойкость эритроцитов при диффузно-токсическом зобе*. Diss. Замонавий клиник лаборатор ташхиси долзарб муаммолари, 2022.
3) Бабаджанова, Ш. А., and Г. Ч. Курбанова. "Феррокинетика при диффузно-токсическом зобе." *Замонавий клиник лаборатор ташхиси долзарб муаммолари* 1 (2022): 101-103.
4) Бабаджанова, Ш. А., Г. Ч. Курбанова, and З. Ч. Курбонова. *Изучение гематологических показателей при диффузно-токсическом зобе*. Diss. Проблемы биофизики и биохимии, 2021.

World Bulletin of Public Health (WBPH)
Available Online at: https://www.scholarexpress.net
Volume-32, March 2024
ISSN: 2749-3644

5) Курбанова, Г. Ч., and Ш. А. Бабаджанова. *Изучение осмотической резистентности эритроцитов при диффузно-токсическом зобе*. Diss. Проблемы биофизики и биохимии, 2021.
6) Курбанова, Г. Ч., and Ш. А. Бабаджанова. *Обмен белка при диффузно-токсическом зобе*. Diss. Проблемы биофизики и биохимии, 2021.
7) Бабаджанова, Ш. А. "Диффуз токсик буқоқ клиник-лаборатор диагностикаси." *Journal of new century innovations* 28.4 (2023): 167-172.
8) Ch, Qurbanova G. *Diffuz toksik buqoqda giperkoagulyasiyaning patogenetik aspektlari*. Diss. KLINIK LABORATOR DIAGNOSTIKADA INNOVATSION TEXNOLOGIYALARDAN FOYDALANISH, MUAMMOLAR VA YECHIMLAR, 2023.
9) Ch, Qurbanova G. *Diffuz toksik buqoq klinik xususiyatlari*. Diss. KLINIK LABORATOR DIAGNOSTIKADA INNOVATSION TEXNOLOGIYALARDAN FOYDALANISH, MUAMMOLAR VA YECHIMLAR, 2023.
10) Ch, Qurbanova G. "DIFFUZ TOKSIK BUQOQ ETIOPATOGENETIK VA KLINIK XUSUSIYATLARI." *JOURNAL OF INNOVATIONS IN SCIENTIFIC AND EDUCATIONAL RESEARCH* 6.4 (2023): 388-394.